1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Renascience Inc.

Renascience Inc.

4889.T
Renascience Inc.JP flagTokyo Stock Exchange
1,525.00
JPY
-4.00
- -
21.01BMarket Cap

Total Valuation

Renascience Inc. carries a market capitalization of 21.01B, placing it among publicly traded companies globally. Its enterprise value stands at 2.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.01B
Enterprise Value2.77B

Share Statistics

Renascience Inc. currently has 12.71M shares outstanding.

Shares Outstanding12.71M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 58.71, and the price-to-book ratio stands at 280.55.

PE RatioN/A
PS Ratio58.71
PB Ratio280.55
P/TBV Ratio2.81
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

EV / Sales37.72
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Renascience Inc. maintains a current ratio of 33.88, meaning it holds 33.9x the short-term assets needed to cover near-term liabilities.

Current Ratio33.88
Quick Ratio33.01
Debt / Equity23.84
Debt / EBITDA-2.32
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-122.24
Return on Assets (ROA)-7.76
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax979,000.00
Effective Tax RateN/A

Stock Price Statistics

Renascience Inc.'s stock has declined approximately -33.31876% over the past 52 weeks. The 50-day moving average sits at 1,486.06, while the 200-day moving average is 1,671.09.

Beta (5Y)N/A
52-Week Price Change-33.31876%
50-Day Moving Average1,486.06
200-Day Moving Average1,671.09
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Renascience Inc. generated 73.39M in revenue and converted that into -163.01M in net income, yielding earnings per share of -12.82. EBITDA reached -157.59M, while operating income came in at -157.59M.

Revenue73.39M
Gross Profit72.14M
Operating Income-157.59M
Pretax Income-162.03M
Net Income-163.01M
EBITDA-157.59M
EBIT-157.59M
Earnings Per Share (EPS)-12.82

Balance Sheet

Renascience Inc. holds 1.91B in cash and equivalents against 365.58M in total debt, resulting in a net debt position of -1.54B. Total book value stands at 15.36M, with working capital of 1.90B providing operational flexibility.

Cash & Cash Equivalents1.91B
Total Debt365.58M
Net Debt-1.54B
Equity (Book Value)15.36M
Book Value Per Share1.21
Working Capital1.90B

Margins

Renascience Inc. operates with a gross margin of 98.30, reflecting its pricing power and cost economics. The operating margin of -214.71 and net profit margin of -222.11 provide insight into operational efficiency.

Gross Margin98.30
Operating Margin-214.71
Pretax Margin-220.77
Profit Margin-222.11
EBITDA Margin-214.71

Scores

Renascience Inc. posts an Altman Z-Score of 6.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.31